{"filing":{"accession_number":"0001171843-26-004708","cik":"0001447028","ticker":"ABUS","company_name":"Arbutus Biopharma Corp","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"f8k_071626.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326004708/f8k_071626.htm"},"events":[{"id":18280,"run_id":16430,"accession_number":"0001171843-26-004708","anchor_item_number":"1.02","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Arbutus terminated its RSV Agreement with Genevant, incurring a $1.0 million termination fee. The termination is part of a broader financial restructuring that includes receipt of approximately $178 million from Moderna and announcement of up to $230 million in capital returns to shareholders.","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17044,"accession_number":"0001171843-26-004708","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of the RSV Agreement with Genevant under Item 1.02, with a $1.0 million termination fee to Arbutus. While Item 1.02 typically covers M\u0026A activity, this termination is a financial settlement of a prior agreement rather than a material acquisition, disposition, or change of control. The supplemental press release reveals the material financial event: receipt of approximately $178 million from Moderna and announcement of up to $230 million in capital returns to shareholders, making this a material financial event that does not fit the specific M\u0026A taxonomy but is clearly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18281,"run_id":16430,"accession_number":"0001171843-26-004708","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board approved one-time lump sum cash bonuses for CEO Lindsay Androski and CFO Tuan Nguyen tied to litigation settlement proceeds, with Androski receiving 1.5% of noncontingent payments ($178M), 2.0% of contingent proceeds, and 2.5% of Pfizer/BioNTech litigation proceeds, and Nguyen receiving 0.25% of noncontingent proceeds and potential future bonuses.","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17045,"accession_number":"0001171843-26-004708","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on Board-approved compensatory arrangements for two named executives: Lindsay Androski (CEO) and Tuan Nguyen (CFO). The Board approved one-time lump sum cash bonuses tied to litigation settlement proceeds—Androski receiving 1.5% of the noncontingent payment ($178M), 2.0% of contingent proceeds, and 2.5% of Pfizer/BioNTech litigation proceeds; Nguyen receiving 0.25% of noncontingent proceeds and potential future bonuses. These are material executive compensation arrangements disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18282,"run_id":16430,"accession_number":"0001171843-26-004708","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"summary":"Arbutus and Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech seeking monetary relief and injunctions against their mRNA-LNP COVID-19 vaccines, asserting Arbutus's LNP patent portfolio.","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17046,"accession_number":"0001171843-26-004708","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on Arbutus and Genevant filing three international patent infringement lawsuits against Pfizer/BioNTech seeking monetary relief and injunctions against their mRNA-LNP COVID-19 vaccines. While the filing also mentions receipt of a $178M Moderna settlement payment and a planned $230M capital return to shareholders, the principal action disclosed is the initiation of material litigation to enforce LNP patents. The litigation is material to investors as it seeks significant monetary damages and injunctions against major competitors' products.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17044,"accession_number":"0001171843-26-004708","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses termination of the RSV Agreement with Genevant under Item 1.02, with a $1.0 million termination fee to Arbutus. While Item 1.02 typically covers M\u0026A activity, this termination is a financial settlement of a prior agreement rather than a material acquisition, disposition, or change of control. The supplemental press release reveals the material financial event: receipt of approximately $178 million from Moderna and announcement of up to $230 million in capital returns to shareholders, making this a material financial event that does not fit the specific M\u0026A taxonomy but is clearly material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16"},{"id":17045,"accession_number":"0001171843-26-004708","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on Board-approved compensatory arrangements for two named executives: Lindsay Androski (CEO) and Tuan Nguyen (CFO). The Board approved one-time lump sum cash bonuses tied to litigation settlement proceeds—Androski receiving 1.5% of the noncontingent payment ($178M), 2.0% of contingent proceeds, and 2.5% of Pfizer/BioNTech litigation proceeds; Nguyen receiving 0.25% of noncontingent proceeds and potential future bonuses. These are material executive compensation arrangements disclosed under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16"},{"id":17046,"accession_number":"0001171843-26-004708","item_number":"8.01","item_title":"Other Events.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.75,"reasoning":"The disclosure centers on Arbutus and Genevant filing three international patent infringement lawsuits against Pfizer/BioNTech seeking monetary relief and injunctions against their mRNA-LNP COVID-19 vaccines. While the filing also mentions receipt of a $178M Moderna settlement payment and a planned $230M capital return to shareholders, the principal action disclosed is the initiation of material litigation to enforce LNP patents. The litigation is material to investors as it seeks significant monetary damages and injunctions against major competitors' products.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:32:51.456634+00:00","company_name":"Arbutus Biopharma Corp","ticker":"ABUS","filing_date":"2026-07-16"}]}